Browsing Tag
Cadrenal Therapeutics
2 posts
Cadrenal Therapeutics shares surge as FDA alignment clears a key hurdle for CAD-1005 Phase 3 strategy
Cadrenal Therapeutics gains FDA alignment on a CAD-1005 Phase 3 trial as CVKD shares surge. See why financing and efficacy remain critical.
CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients
Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.